Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
Kunal C. Kadakia(University of Michigan), N. Lynn Henry(University of Michigan), Claire Snyder(Johns Hopkins University), James M. Rae(University of Michigan), Anna Maria Storniolo(Indiana University Health), Vered Stearns(Johns Hopkins University), Kelley M. Kidwell(University of Michigan), Daniel F. Hayes(University of Michigan–Ann Arbor), Nicholas J. Seewald(University of Michigan), Julie L. Otte(Indiana University – Purdue University Indianapolis), David A. Flockhart(Indiana University – Purdue University Indianapolis), Todd C. Skaar(Indiana University School of Medicine), Zereunesay Desta(Indiana University Health), Janet S. Carpenter(Indiana University – Purdue University Indianapolis)
Cited by 76
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k